Movement Alert｜BIOCYTOGEN-B Intraday Rise 18.17% in Regular Trading, Earnings Strength and Recent Institutional Buying Supported the Rebound

On November 4, BIOCYTOGEN-B rose 18.17% intraday in Regular Trading, trading at HK$42.62, with turnover of HK$80.71 million.

The move aligns with the most recent market interpretation that the stock was supported by strong third-quarter results and recent on-market institutional buying, even after the company’s latest monthly share report showed no change in issued share capital.

Background disclosures showed BIOCYTOGEN-B reported revenue of RMB1.403 billion for the first three quarters, up 49.09% year over year, with attributable net profit of RMB312 million, up 173.77%, and operating cash flow of RMB422 million, exceeding the prior full-year level. Separately, E Fund increased its long position to 6.01% after buying 86,000 shares on October 27, while FMR LLC raised its long position to 5.04% after buying 100,500 shares on October 28 at an average price of HK$42.3527 per share. The current rebound brought the stock back near that latest disclosed institutional purchase price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)